From June 24 to 25, during the 23rd World Pharmaceutical Raw Materials China Exhibition, the 14th Forum on Innovation and Development of the Pharmaceutical Industry was successfully held in Shanghai. This forum conducted special discussions on hot topics such as the trends of economic and trade restriction measures of the U.S. Trump administration, underwriting and risk analysis of the biopharmaceutical industry chain, review and analysis of China's pharmaceutical industry development during the "14th Five-Year Plan" and outlook on the development situation during the "15th Five-Year Plan", the impact and trend prediction of new policies on the pharmaceutical industry, the main characteristics of current pharmaceutical industry development, the development status of China's generic drug industry, the trends and strategies of pharmaceutical companies entering emerging markets, countermeasures for Chinese export enterprises under the background of Sino-U.S. trade frictions, and the core advantages of industrial parks. Luo Yang, Deputy Secretary-General of the China Chamber of Commerce for Import and Export of Medicines and Health Products, attended the forum and delivered a speech. Xu Ningru, Deputy Director of the Legal and Comprehensive Department, presided over the forum.

In his speech, Deputy Secretary-General Luo Yang mentioned that the pharmaceutical industry is related to national health, social stability and economic development, and is universally recognized as the most promising competitive industry in the world. After years of accumulation, China's pharmaceutical industry has increasingly strong endogenous motivation to participate in international division of labor and cooperation, with continuous expansion in breadth and depth. At present, China has become the world's largest producer of APIs and small and medium-sized medical devices and equipment, and is playing an increasingly important role in the global pharmaceutical industry pattern. Currently, trade protectionism is intensifying. The Trump administration's abuse of tariff policies has caused market chaos, disrupted the global economic and trade order, the global economic and trade environment is facing more uncertain factors, and the international pharmaceutical industry value chain is undergoing profound adjustments. Under the new situation, how pharmaceutical enterprises, as the main players in market competition, can take advantage of the situation to enhance their international competitiveness and realize the new international layout and development of China's pharmaceutical industry is particularly important and of strategic significance. This is also the original intention of holding the Forum on Innovation and Development of the Pharmaceutical Industry.

Since February this year, the U.S. Trump administration has launched a new round of tariff war against China. This tariff game not only affects the sensitive nerves of Sino-U.S. relations, but also triggers a wave of trade protectionism worldwide. The forum invited Wang Jianfeng, Director of the Trade Remedy Investigation Bureau of the Ministry of Commerce, to give a keynote speech on the trends of the economic and trade restriction measures of the U.S. Trump administration. Director Wang made an introduction from the aspects of three memorandums, three types of tariffs, non-tariff measures and new trends in the field of trade remedies. He said that the U.S. unilateral and protectionist acts have undermined the rules-based multilateral trading system, seriously threatened the stability of the industrial and supply chains including pharmaceutical products, and interfered with and disrupted market rules and the international economic and trade order. Relevant government departments will continue to help enterprises actively respond to unreasonable trade restriction measures and safeguard the legitimate rights and interests of Chinese enterprises.

Export credit insurance is no stranger to export enterprises, especially in encouraging and promoting export trade and ensuring the safety of foreign exchange collection for export enterprises, it plays a pivotal role. Yang Qi, Director of the Trade Insurance Underwriting Department of China Export & Credit Insurance Corporation (Sinosure), gave a keynote speech at the forum on "New Opportunities, New Development - Underwriting and Risk Analysis of the Biopharmaceutical Industry Chain". With his years of rich experience in underwriting overseas markets and the biopharmaceutical industry chain, Director Yang introduced the support for the biopharmaceutical industry chain, the risk trends and characteristics of the industry chain, and the development and risk control of export enterprises. While mastering relevant policies, enterprises further enhanced their confidence in going global.

In recent years, Tongcheng City, Anhui Province, has been committed to the transformation and upgrading of traditional industries and the development and growth of emerging industries, forming characteristic industrial clusters of "two new and one medical" (new energy, new materials and medical industry), such as new energy vehicle parts, photovoltaic new energy, and medical engineering and pharmaceuticals. At the meeting, Li Yuanyuan, Director of the Management Committee of Tongcheng Economic and Technological Development Zone, Anhui Province, introduced the basic situation of Tongcheng City and Tongcheng Pharmaceutical and Chemical Park from multiple dimensions such as culture, history, industrial foundation and business environment. She said that Tongcheng Chemical Park has a clear leading industry, can make full use of resource endowments and comparative advantages, focus on building an industrial cluster with isotopes and related industries as the core, and has achieved positive results in industrial agglomeration development, efficient project promotion, and high-quality enterprise services. It is hoped that through the opportunity of this forum, it can better empower the high-quality development of Tongcheng's pharmaceutical and health industry.

This year is the closing year of the "14th Five-Year Plan" and the year for planning the "15th Five-Year Plan". The forum invited Cao Huili, Director of the Consumer Goods Industry Research Institute of CCID Think Tank of the Ministry of Industry and Information Technology, who took the lead in organizing the drafting of the "15th Five-Year Plan" for the development of the pharmaceutical industry of the Ministry of Industry and Information Technology, to share the progress of the "14th Five-Year Plan" and the outlook for the "15th Five-Year Plan", helping enterprises better grasp the macro development trend in the pharmaceutical field, which received positive feedback from participating enterprises.

Zhang Ziran, specially invited Vice President of the China Chemical Pharmaceutical Industry Association, based on data, analyzed the new changes and trends of China's pharmaceutical industry under the current policy optimization and innovation drive. He said that in recent years, China's medical reform has been deepened, the review and approval of new drugs have been accelerated, the listing of new drugs and their inclusion in medical insurance have been speeded up, and China's accession to ICH has opened a fast track for innovative drugs to go global and pharmaceutical companies to globalize. In addition, the consistency evaluation of generic drugs has promoted the transformation and upgrading of a large number of traditional pharmaceutical enterprises, the industry concentration has been continuously improved, and patients' access to drugs has been significantly enhanced.

The pharmaceutical industry is a strategic industry related to national economy and people's livelihood, economic development and social stability. On the morning of the 25th, Chi Xiaowei, Deputy Secretary-General of the China Pharmaceutical Enterprise Management Association, used detailed industry data to conduct an in-depth analysis of the main characteristics of the current pharmaceutical industry development from 13 aspects, including the policy environment, revenue and profits, generic drug competition, innovative drug scale, and the tendency of chemical APIs towards industrial chain collaboration. He said that the advantages of API manufacturing have been consolidated and enhanced, the biological drug industry such as antibody drugs and new vaccines has been continuously developing and growing, and the pharmaceutical industry is accelerating its extension to the high end of the value chain. Driven by both policy support and technological breakthroughs, China's pharmaceutical industry is moving towards a new stage of high-quality development.

Su Hong, Consulting Director of China Pharmaceutical Industry Information Center, first talked about the important value of generic drugs in reducing drug costs, accelerating accessibility, enhancing supply resilience, and promoting industrial upgrading. She expounded the development status of generic drugs from multiple perspectives such as the market scale, main components, R&D choices, market concentration, revenue situation, and homogeneous competition of generic drugs in China, and put forward thoughts on development.

Wang Lifeng, Secretary-General of the International Cooperation Working Committee of the China Non-Prescription Medicines Association, conducted in-depth discussions and exchanges with the on-site audience on the topic of trends and strategies for entering emerging markets. Secretary-General Wang introduced the process of China's pharmaceutical industry integrating into the global pharmaceutical industry chain through three timelines of China's pharmaceutical industry's global expansion. He elaborated on the advantages and opportunities of Chinese pharmaceutical enterprises going global, emphasizing that China's huge market scale and complete industrial chain advantages are the cornerstone of China's pharmaceutical innovation, and also enable Chinese biopharmaceutical enterprises to have the ability to expand overseas. He also looked forward to the overseas expansion of Chinese pharmaceutical enterprises through the study of foreign cases and combined with his own practice and experience.

Wang Tongzhou, a lawyer from AllBright Law Offices, combined with years of practical experience, shared the countermeasures for Chinese export enterprises under the background of Sino-U.S. trade frictions, which enterprises are concerned about. She first sorted out the U.S. Trump administration's "reciprocal tariff" policy and the Chinese government's countermeasures against the "reciprocal tariff" policy. While talking about the profound impact of the U.S. government's reciprocal tariff policy on the global supply chain system and Chinese export-oriented manufacturing enterprises, she put forward ten suggestions for enterprises to effectively respond, which were highly praised by the enterprises present.

The Forum on Innovation and Development of the Pharmaceutical Industry has been held 14 times so far. The 14 years of trials and tribulations, exploration and innovation are enough to prove that the Forum on Innovation and Development is a stage for ideological collision, inspiration and seeking common development. We hope that through this forum, we can provide high-level regular exchange opportunities for domestic and foreign pharmaceutical entrepreneurs, industry experts and relevant government departments, so that everyone can focus on the future development of the industry, with a global strategic perspective, keenly insight into and in-depth analyze the new environment and new situation of the development of Chinese and foreign pharmaceutical industries. Continuously integrate the latest information, concepts and wisdom into the development of enterprises and industries, promote and deepen exchanges and cooperation between Chinese and foreign pharmaceutical enterprises, and make due contributions to the transformation of China from a major pharmaceutical country to a pharmaceutical power as soon as possible.

https://www.cccmhpie.org.cn/newsinfo/8491030.html